Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.

BMC gastroenterology - 6 Apr 2020

Tayyab Ghias Un Nabi, Rasool Shafqat, Nasir Bilal, Rubi Ghazala, Abou-Samra Abdul-Badi, Butt Adeel A

Abstract excerpt

BACKGROUND: There are conflicting data regarding the risk of hepatocellular carcinoma (HCC) after direct-acting antiviral agent (DAA) treatment. Risk of HCC in HCV genotype-3 infected persons after DAA therapy is not well known. METHODS: We prospectively studied HCV infected persons initiated on a DAA regimen between October 2014 and March 2017 at two centers in Pakistan. All persons were free of HCC at study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Pakistan

Share to Polyethylene Glycols

Share to Pyrrolidines

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Open in PubMed Open full text

Identifiers

PMID: 32252635
DOI: 10.1186/s12876-020-01249-4
PMCID: PMC7137260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.PMID 32252635Read ↗

DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA.Semantic proximity Read ↗

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.Semantic proximity Read ↗

Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study.Semantic proximity Read ↗

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.Semantic proximity Read ↗

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.Semantic proximity Read ↗

Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.Semantic proximity Read ↗

Epidemiology of viral hepatitis and hepatocellular carcinoma.Semantic proximity Read ↗

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of EpigeneticsSemantic proximity Read ↗

Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort.Semantic proximity Read ↗

Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience.Semantic proximity Read ↗

Hepatitis C virus-induced hepatocellular carcinoma: a narrative review.Semantic proximity Read ↗

Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.